Cargando…
Modeling of lung phenotype of Hermansky–Pudlak syndrome type I using patient-specific iPSCs
BACKGROUND: Somatic cells differentiated from patient-specific human induced pluripotent stem cells (iPSCs) could be a useful tool in human cell-based disease research. Hermansky–Pudlak syndrome (HPS) is an autosomal recessive genetic disorder characterized by oculocutaneous albinism and a platelet...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8570015/ https://www.ncbi.nlm.nih.gov/pubmed/34736469 http://dx.doi.org/10.1186/s12931-021-01877-8 |
_version_ | 1784594757827166208 |
---|---|
author | Suezawa, Takahiro Kanagaki, Shuhei Korogi, Yohei Nakao, Kazuhisa Hirai, Toyohiro Murakami, Koji Hagiwara, Masatoshi Gotoh, Shimpei |
author_facet | Suezawa, Takahiro Kanagaki, Shuhei Korogi, Yohei Nakao, Kazuhisa Hirai, Toyohiro Murakami, Koji Hagiwara, Masatoshi Gotoh, Shimpei |
author_sort | Suezawa, Takahiro |
collection | PubMed |
description | BACKGROUND: Somatic cells differentiated from patient-specific human induced pluripotent stem cells (iPSCs) could be a useful tool in human cell-based disease research. Hermansky–Pudlak syndrome (HPS) is an autosomal recessive genetic disorder characterized by oculocutaneous albinism and a platelet dysfunction. HPS patients often suffer from lethal HPS associated interstitial pneumonia (HPSIP). Lung transplantation has been the only treatment for HPSIP. Lysosome-related organelles are impaired in HPS, thereby disrupting alveolar type 2 (AT2) cells with lamellar bodies. HPSIP lungs are characterized by enlarged lamellar bodies. Despite species differences between human and mouse in HPSIP, most studies have been conducted in mice since culturing human AT2 cells is difficult. METHODS: We generated patient-specific iPSCs from patient-derived fibroblasts with the most common bi-allelic variant, c.1472_1487dup16, in HPS1 for modeling severe phenotypes of HPSIP. We then corrected the variant of patient-specific iPSCs using CRISPR-based microhomology-mediated end joining to obtain isogenic controls. The iPSCs were then differentiated into lung epithelial cells using two different lung organoid models, lung bud organoids (LBOs) and alveolar organoids (AOs), and explored the phenotypes contributing to the pathogenesis of HPSIP using transcriptomic and proteomic analyses. RESULTS: The LBOs derived from patient-specific iPSCs successfully recapitulated the abnormalities in morphology and size. Proteomic analysis of AOs involving iPSC-derived AT2 cells and primary lung fibroblasts revealed mitochondrial dysfunction in HPS1 patient-specific alveolar epithelial cells. Further, giant lamellar bodies were recapitulated in patient-specific AT2 cells. CONCLUSIONS: The HPS1 patient-specific iPSCs and their gene-corrected counterparts generated in this study could be a new research tool for understanding the pathogenesis of HPSIP caused by HPS1 deficiency in humans. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12931-021-01877-8. |
format | Online Article Text |
id | pubmed-8570015 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-85700152021-11-08 Modeling of lung phenotype of Hermansky–Pudlak syndrome type I using patient-specific iPSCs Suezawa, Takahiro Kanagaki, Shuhei Korogi, Yohei Nakao, Kazuhisa Hirai, Toyohiro Murakami, Koji Hagiwara, Masatoshi Gotoh, Shimpei Respir Res Research BACKGROUND: Somatic cells differentiated from patient-specific human induced pluripotent stem cells (iPSCs) could be a useful tool in human cell-based disease research. Hermansky–Pudlak syndrome (HPS) is an autosomal recessive genetic disorder characterized by oculocutaneous albinism and a platelet dysfunction. HPS patients often suffer from lethal HPS associated interstitial pneumonia (HPSIP). Lung transplantation has been the only treatment for HPSIP. Lysosome-related organelles are impaired in HPS, thereby disrupting alveolar type 2 (AT2) cells with lamellar bodies. HPSIP lungs are characterized by enlarged lamellar bodies. Despite species differences between human and mouse in HPSIP, most studies have been conducted in mice since culturing human AT2 cells is difficult. METHODS: We generated patient-specific iPSCs from patient-derived fibroblasts with the most common bi-allelic variant, c.1472_1487dup16, in HPS1 for modeling severe phenotypes of HPSIP. We then corrected the variant of patient-specific iPSCs using CRISPR-based microhomology-mediated end joining to obtain isogenic controls. The iPSCs were then differentiated into lung epithelial cells using two different lung organoid models, lung bud organoids (LBOs) and alveolar organoids (AOs), and explored the phenotypes contributing to the pathogenesis of HPSIP using transcriptomic and proteomic analyses. RESULTS: The LBOs derived from patient-specific iPSCs successfully recapitulated the abnormalities in morphology and size. Proteomic analysis of AOs involving iPSC-derived AT2 cells and primary lung fibroblasts revealed mitochondrial dysfunction in HPS1 patient-specific alveolar epithelial cells. Further, giant lamellar bodies were recapitulated in patient-specific AT2 cells. CONCLUSIONS: The HPS1 patient-specific iPSCs and their gene-corrected counterparts generated in this study could be a new research tool for understanding the pathogenesis of HPSIP caused by HPS1 deficiency in humans. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12931-021-01877-8. BioMed Central 2021-11-04 2021 /pmc/articles/PMC8570015/ /pubmed/34736469 http://dx.doi.org/10.1186/s12931-021-01877-8 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Suezawa, Takahiro Kanagaki, Shuhei Korogi, Yohei Nakao, Kazuhisa Hirai, Toyohiro Murakami, Koji Hagiwara, Masatoshi Gotoh, Shimpei Modeling of lung phenotype of Hermansky–Pudlak syndrome type I using patient-specific iPSCs |
title | Modeling of lung phenotype of Hermansky–Pudlak syndrome type I using patient-specific iPSCs |
title_full | Modeling of lung phenotype of Hermansky–Pudlak syndrome type I using patient-specific iPSCs |
title_fullStr | Modeling of lung phenotype of Hermansky–Pudlak syndrome type I using patient-specific iPSCs |
title_full_unstemmed | Modeling of lung phenotype of Hermansky–Pudlak syndrome type I using patient-specific iPSCs |
title_short | Modeling of lung phenotype of Hermansky–Pudlak syndrome type I using patient-specific iPSCs |
title_sort | modeling of lung phenotype of hermansky–pudlak syndrome type i using patient-specific ipscs |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8570015/ https://www.ncbi.nlm.nih.gov/pubmed/34736469 http://dx.doi.org/10.1186/s12931-021-01877-8 |
work_keys_str_mv | AT suezawatakahiro modelingoflungphenotypeofhermanskypudlaksyndrometypeiusingpatientspecificipscs AT kanagakishuhei modelingoflungphenotypeofhermanskypudlaksyndrometypeiusingpatientspecificipscs AT korogiyohei modelingoflungphenotypeofhermanskypudlaksyndrometypeiusingpatientspecificipscs AT nakaokazuhisa modelingoflungphenotypeofhermanskypudlaksyndrometypeiusingpatientspecificipscs AT hiraitoyohiro modelingoflungphenotypeofhermanskypudlaksyndrometypeiusingpatientspecificipscs AT murakamikoji modelingoflungphenotypeofhermanskypudlaksyndrometypeiusingpatientspecificipscs AT hagiwaramasatoshi modelingoflungphenotypeofhermanskypudlaksyndrometypeiusingpatientspecificipscs AT gotohshimpei modelingoflungphenotypeofhermanskypudlaksyndrometypeiusingpatientspecificipscs |